Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686368 | 0.87 | ALDH1A1 (0.45) | TSHRALDH1A1HPGD | |
| SCHEMBL2686310 | 0.85 | HPGD (0.48) | SMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL2687606 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRKMT2AMEN1TP53 | |
| SCHEMBL18485318 | 0.80 | ALDH1A1 (0.43) | SMN1; SMN2TSHRKMT2AMEN1TP53 | |
| SCHEMBL5761060 | 0.80 | ALDH1A1 (0.43) | SMN1; SMN2TSHRKMT2AMEN1TP53 | |
| SCHEMBL21755101 | 0.79 | TSHR (0.41) | SMN1; SMN2TSHRKMT2AMEN1TP53 | |
| SCHEMBL16424010 | 0.76 | ALDH1A1 (0.45) | SMN1; SMN2TSHRKMT2AMEN1TP53 | |
| SCHEMBL20405434 | 0.75 | ALDH1A1 (0.61) | SMN1; SMN2TSHRKMT2AMEN1MAPK1 | |
| SCHEMBL2687790 | 0.74 | TSHR (0.56) | SMN1; SMN2TSHRKMT2AMEN1MAPK1 | |
| SCHEMBL2343227 | 0.73 | EPHX1 (0.59) | KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | claimed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | claimed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | claimed |
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | SMN1; SMN2 1773/4885TSHR 4114/4885KMT2A 961/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | SMN1; SMN2 1773/4885TSHR 4114/4885KMT2A 961/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | SMN1; SMN2 1773/4885TSHR 4114/4885KMT2A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.